4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases.
Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P-Pharma is the dual leverage of in-house R&D capabilities combined with Single Product Vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.
4P-Pharma aims to bring to patients’ curative solutions faster by moving away from current linear pharmaceutical development towards circular one :
We aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI based biotechs.
Our R&D capabilities within Pasteur Institute at Lille allow us to assess breakthrough innovations by regenerating active drugs as proprietary first-in-class therapies in the new indication.
Once reaching regulatory milestones, we launch single product vehicles allowing rapid initiation of clinical trials and enabling big pharma collaborations to facilitate access of innovative medicines to patients.
4Living Biotech is dedicated to the clinical development of 4P021, a drug candidate for a curative treatment of acute and chronic pulmonary complications due to viral infection.
4Living Biotech is launching its first international proof of concept phase 2b trial to evaluate the potential of a CXCR4 antagonist to cure severe hospitalized Covid-19 patients.
4Living Biotech entered in a clinical collaboration with Sanofi.
4Moving Biotech is dedicated to the clinical development of 4P004, a disease modifying drug candidate for osteoarthritis showing anti-inflammatory, anti-catabolic and anabolic properties.
4Moving Biotech is launching a phase 1 clinical trial on knee OA patients, to assess intra-articular pharmacokinetic and safety of a GLP-1 analog.
Respiratory infectionPharmaceutical partner:
Sanofi
Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute and chronic pulmonary complications due to viral infection.
A first international proof of concept phase 2b trial is launched to evaluate the potential of a CXCR4 antagonist to cure severe hospitalized Covid-19 patients.
4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.
Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.
Milestone:
Phase II trial on Covid-19 patients.
Epidemiology:
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).
OsteoarthritisPharmaceutical partner:
Partnering opportunity
Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.
4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech.
Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.
Milestone:
Phase I trial on OA patients
Market:
≥ 300 Millions of people have OA in the world (Kloppenburg et al., 2020)
Estimated sales per year : 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)
Our team, our key driver for our success
4P-Pharma is a passionate and complementary team of drug developers, combining scientific, clinical, pharmaceutical, financial, and business experts, and sharing the same vision: bring curative therapies to people with serious diseases.
Our young, human-sized team of 15 employees is always happy to welcome new talents. Each of our employees is amazing, but it is together that we make 4P-Pharma such a dynamic, proactive and creative company.
En tant que scientifique, associez-vous un ou des objectifs spécifiques à votre activité de recherche ? Si oui lequel ou lesquels ? Pr. Canaud: Oui effectivement, je me pose, ou plutôt nous nous posons car il s’agit d’un travail d’équipe, deux questions clés : 1-Comment cela fonctionne-t-il ? 2-Comment utiliser nos connaissances pour améliorer la vie des&hellip
Revital Rattenbach, 4P-Pharma’s chairwoman has been interviewed by Stéphane Soumier in “Smart Morning Soumier”. The program is broadcasted on June 30th, 2022, on B SMART TV and RTL. For more information: click here
4P-Pharma and Delta 4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under this agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available. Kurt Herpel, CEO of Delta4 commented that “We are looking forward to&hellip
